Altre lingue Beam Therapeutics Inc.

Azioni

BEAM

US07373V1052

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 24/04/2024			Variaz. 5gg	Var. 1 gen.
22,74 ^USD	-2,99%		-6,46%	-16,46%

04/04	L'insider di Beam Therapeutics ha venduto azioni per un valore di 581.617 dollari, secondo un recente documento della SEC	MT
04/04	Un insider di Beam Therapeutics ha venduto azioni per un valore di 734.805 dollari, secondo un recente documento della SEC	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	04/04
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	04/04
Beam Therapeutics Says BEAM-302 Drug Candidate Gets UK Clearance for Alpha-1 Antitrypsin Deficiency	26/03
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	26/03
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	26/03
Beam Therapeutics Inc. Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency	26/03
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences	28/02
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences	28/02
Health Care Down as Viking Move Rattles Novo Shares -- Health Care Roundup	27/02
Beam Therapeutics Shares Jump on Surprise Q4 Profit	27/02
Beam Therapeutics Reports Surprise Q4 Profit; Shares Jump in Early Trading	27/02
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones	27/02
Beam Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	05/02
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	05/02
Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto	30/01
North American Morning Briefing : Microsoft Kicks -2-	30/01
Beam Therapeutics Shares Gain Following JPMorgan's Upgrade to Overweight	29/01
Rapport Therapeutics Appoints Terry-Ann Burrell to Board of Directors	17/01
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones	08/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

In prima pagina

Gli ETF su Bitcoin sono fantastici, ma non sono la vera criptovaluta: CEO di Beam

30 gennaio 2024 alle 20:21